In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor

被引:51
|
作者
Singh, Pushpendra [1 ]
Bast, Felix [1 ]
机构
[1] Cent Univ Punjab, Ctr Biosci, Sch Basic & Appl Sci, Bathinda 151001, Punjab, India
关键词
Cancer; Epidermal growth factor receptor; Mutation; Natural compound; Maestro 9.3 (Schrodinger 2012); CELL LUNG-CANCER; PROSTATE-CANCER; KINASE INHIBITORS; TYROSINE KINASES; ANDROGEN RECEPTOR; ACCURATE DOCKING; DOWN-REGULATION; T790M MUTATION; EGFR T790M; GEFITINIB;
D O I
10.1007/s00044-014-1090-1
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The role played by overexpression of tyrosine kinase epidermal growth factor receptor (EGFR), the transmembrane receptor central to numerous cellular processes comprising cell migration, adhesion, apoptosis, and cell proliferation, has been highlighted in various cancers such as prostate, breast, lung, and ovarian cancers as well as in mutations in the EGFR kinase domain. Although many therapeutic approaches have targetted EGFR, the mutations occurring in the EGFR kinase domain including L858 EGFR and T790/L858R had led to the amplification of EGFR signals, consequently leading to increased cell proliferation and cell growth. The strategies involving the inhibition of EGFR L858 and T790M have been accredited with limited achievement in addition to being associated with unwanted adverse effects as a result of crosstalk of wild-type EGFR. All current EGFR tyrosine kinase inhibitors have been identified as ATP competitive inhibitors of wild-type EGFR possessing aniline and quinazoline moiety on the ligands skeleton. Our results obtained by performing molecular docking study on Maestro 9.3 molecular docking suite indicated that CID5280343 possesses better energy conformation against wild-type EGFR as well as two mutated EGFR. Moreover, it was discovered in this study that the natural compounds CID72276, CID5280445, CID441794, and CID72277 and InterBioScreen's library STOCK1N-78657, STOCK1N-78976, and STOCK1N-78847 have better binding conformation against gatekeeper T790M mutated EGFR concluded to be brought about by means of flexible ligands/receptor-based molecular docking protocol. Miraculous features of these compounds are their various pharmacokinetic and pharmacodynamic parameters which were found to be satisfactory as drug-like molecules. This molecular docking study also summarizes docking free energy, protein-ligands interaction profile, and pharmacokinetic and pharmacodynamic parameter of lead molecules which were tremendously helpful in enhancing the activity of these natural compounds against EGFR.
引用
收藏
页码:5074 / 5085
页数:12
相关论文
共 50 条
  • [1] In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor
    Pushpendra Singh
    Felix Bast
    Medicinal Chemistry Research, 2014, 23 : 5074 - 5085
  • [2] Docking and Molecular Dynamics Study on the Inhibitory Activity of Novel Inhibitors on Epidermal Growth Factor Receptor (EGFR)
    Liao, Qing-Hua
    Gao, Qing-Zhi
    Wei, Jing
    Chou, Kuo-Chen
    MEDICINAL CHEMISTRY, 2011, 7 (01) : 24 - 31
  • [3] Molecular Docking and Molecular Dynamics Simulations of the Kinase Domain Inhibitor for an Epidermal Growth Factor Receptor
    Choi, Youngjin
    Kang, In-Cheol
    Cho, Eunae
    Kim, Jaebum
    Jeong, Karpjoo
    Jung, Seunho
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2013, 34 (08): : 2515 - 2518
  • [4] Molecular docking of ferulic acid analogue compounds against epidermal growth factor receptor as a potential therapy for breast cancer
    Ainurrizma, Dhea Ananda
    Ekowati, Juni
    Pebrianti, Denayu
    Diyah, Nuzul Wahyuning
    Adrianto, Muhammad Faris
    Deevi, Ravi Kiran
    Hamid, Iwan Sahrial
    PHARMACY EDUCATION, 2024, 24 (03): : 185 - 190
  • [5] Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors
    Moiseenko, Fedor
    Kuligina, Ekaterina
    Elsakova, Ekaterina
    Imyanitov, Evgeny
    FUTURE ONCOLOGY, 2024, 20 (31) : 2397 - 2407
  • [6] In silico Study of Thiourea Derivatives as Potential Epidermal Growth Factor Receptor Inhibitors
    Roslan, Norashikin
    Halim, Khairul Bariyyah Abd.
    Bunnori, Noraslinda Muhamad
    Aluwi, Mohd Fadhlizil Fasihi Mohd
    Kassim, Karimah
    Ngah, Nurziana
    JOURNAL OF COMPUTATIONAL BIOPHYSICS AND CHEMISTRY, 2023, 22 (04): : 453 - 472
  • [7] In-Silico Evaluation, Chemical Reactivity, and Covalent Docking Study of Various Quinazolines and Pyridopyrimidines as Inhibitors for the Epidermal Growth Factor Receptor
    Khelfaoui, Hadjer
    Harkati, Dalal
    Saleh, Basil A.
    Hewitt, Natalie L.
    Alnajjar, Radwan
    El-Hiti, Gamal A.
    POLYCYCLIC AROMATIC COMPOUNDS, 2024, 44 (05) : 3532 - 3557
  • [8] Natural antifibrosis potential of anthocyanin in Ipomoea batatas against Transforming Growth Factor beta Type II receptor by in silico ADMET and molecular docking study
    Lusiana, Evi
    Sinaga, Ernawati
    Hafy, Zen
    Harahap, Debby Handayati
    Amin, Ramzi
    Saleh, Irsan
    RESULTS IN CHEMISTRY, 2025, 13
  • [9] Targeting Epidermal Growth Factor Receptor with Ficus virens Metabolites to Manage Cancer Progression: Molecular Docking and ADME Study
    Alqurashi, Yaser E.
    Jamal, Azfar
    ADVANCES IN HUMAN BIOLOGY, 2024, 14 (03) : 227 - 234
  • [10] Synthesis, crystal structure and molecular docking study of new monastrol analogues as inhibitors of epidermal growth factor receptor tyrosine kinase
    Wazalwar, Sachin S.
    Banpurkar, Anita R.
    Perdih, Franc
    JOURNAL OF MOLECULAR STRUCTURE, 2023, 1274